PhRMA Joins with National Minority Quality Forum and Microsoft to Address Diversity in Clinical Trials
WASHINGTON, D.C. (June 18, 2013) – The Pharmaceutical Research and Manufacturers of America (PhRMA) announced today that it is partnering with the National Minority Quality Forum (NMQF) and Microsoft to help increase diversity in clinical trials.
PhRMA Statement on Supreme Court Ruling in Patent Settlement Case
WASHINGTON, D.C. (June 17, 2013) – Pharmaceutical Research and Manufacturers of America (PhRMA) Executive Vice President and General Counsel Mit Spears issued the following statement on the decision issued today by the U.S. Supreme Court in the case of Federal Trade Commission v. Actavis, Inc.:
Last week, we took another step in our fight against chronic disease by extending our successful partnership with the Women in Government Foundation, Inc. (WIG), a national non-profit, non-partisan organization of women state legislators.
The first step toward finding solutions in our health care ecosystem is to identify what works, protect what is successful and fix what isn’t. This includes access to medicines, continued research and development and developing programs that get patients the treatments they need.
Part D Preserves Access to Medicines for Beneficiaries with Diabetes
06.12.13 | By
The Annals of Internal Medicine recently published a study that compared prescription diabetes medicine use between Medicare Part D and the Veterans Affairs (VA) program, specifically focusing on generic drug use. The study and subsequent media coverage overlook some important facts about prescription drug coverage in these two programs.
Every 39 seconds an American dies from cardiovascular disease, and more than 83 million Americans have at least one type of the disease, the American Heart Association (AHA) reports. But today, America’s biopharmaceutical research companies are developing 215 medicines for two of the leading causes of death of Americans – heart disease and stroke.